Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 6% Improvement Relative Risk Colchicine  Rodriguez-Nava et al.  LATE TREATMENT Is late treatment with colchicine beneficial for COVID-19? Retrospective 313 patients in the USA No significant difference in mortality c19early.org Rodriguez-Nava et al., Mayo Clinic Pro.., Nov 2020 Favors colchicine Favors control

Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study

Rodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.00000018 from 53 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support. Confounding by indication likely.
This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely; excessive unadjusted differences between groups; unadjusted results with no group details.
Study covers colchicine and HCQ.
risk of death, 5.5% lower, RR 0.94, p = 0.87, treatment 16 of 52 (30.8%), control 85 of 261 (32.6%), NNT 56, unadjusted.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rodriguez-Nava et al., 5 Nov 2020, retrospective, USA, peer-reviewed, median age 68.0, 8 authors, dosage not specified.
This PaperColchicineAll
Clinical Characteristics and Risk Factors for Death of Hospitalized Patients With COVID-19 in a Community Hospital: A Retrospective Cohort Study
MD Guillermo Rodriguez-Nava, MD; Daniela Maria Adriana Yanez-Bello, Daniela Patricia Trelles-Garcia, Chul Won Chung, MD Sana Chaudry, MD Aimen S Khan, MD, FACP Harvey J Friedman, MD David W Hines
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, doi:10.1016/j.mayocpiqo.2020.10.007
Objective: To describe the clinical characteristics, outcomes, and risk factors for death of patients with coronavirus disease 2019 (COVID-19) in a community hospital setting. Patients and Methods: This single-center retrospective cohort study included 313 adult patients with laboratory-confirmed COVID-19 admitted to a community hospital in Cook County, Illinois, from March 1, 2020, to May 25, 2020. Demographics, medical history, underlying comorbidities, symptoms, signs, laboratory findings, imaging studies, management, and progression to discharge or death data were collected and analyzed. Results: Of 313 patients, the median age was 68 years (interquartile range, 59.0-78.5 years; range, 19-98 years), 182 (58.1%) were male, 119 (38%) were white, and 194 (62%) were admitted from a long-term care facility (LTCF). As of May 25, 2020, there were 212 (67.7%) survivors identified, whereas 101 (32.3%) nonsurvivors were identified. Multivariable Cox regression analysis showed increasing hazards of inpatient death associated with older age (hazard ratio [HR] 1.02; 95% CI, 1.01-1.04), LTCF residence (HR, 3.23; 95% CI, 1.68-6.20), and quick Sequential Organ Failure Assessment scores (HR, 2.59; 95% CI, 1.78-3.76). Conclusion: In this single-center retrospective cohort study of 313 adult patients hospitalized with COVID-19 illness in a community hospital in Cook County, Illinois, older patients, LTCF residents, and patients with high quick Sequential Organ Failure Assessment scores were found to have worse clinical outcomes and increased risk of death.
References
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Colaneri, Sacchi, Zuccaro, Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28, Euro Surveill
Docherty, Harrison, Green, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study, BMJ
Ferguson, Rosser, Quintero, Characteristics and outcomes of coronavirus disease patients under nonsurge conditions, northern California, USA, March, Emerg Infect Dis
Garg, Kim, Whitaker, Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019dCOVID-NET, 14 states, MMWR Morb Mortal Wkly Rep
Gold, Wong, Szablewski, Characteristics and clinical outcomes of adult patients hospitalized with COVID-19dGeorgia, March 2020, MMWR Morb Mortal Wkly Rep
Goyal, Choi, Pinheiro, Clinical characteristics of Covid-19 in New York City, N Engl J Med
Guan, Ni, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Heinze, Wallisch, Dunkler, Variable selectionda review and recommendations for the practicing statistician, Biom J
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Kindig, Seplaki, Libby, Death rate variation in US subpopulations, Bull World Health Organ
Lewnard, Vincent, Jackson, Incidence, clinical outcomes, and transmission dynamics of hospitalized 2019 coronavirus disease among 9,596,321 individuals residing in California and, doi:10.1101/2020.04.12.20062943v1
Mathur, Ding, Riddell, Vanderweele, Web site and R package for computing E-values, Epidemiology
Myers, Parodi, Escobar, Liu, Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California, JAMA
Petrilli, Jones, Yang, Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study, BMJ
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Rubin, Falkson, Degner, Blish, Clinical characteristics associated with COVID-19 severity in California, J Clin Transl Sci
Spruance, Reid, Grace, Samore, Hazard ratio in clinical trials, Antimicrob Agents Chemother
Vanderweele, Ding, Sensitivity analysis in observational research: introducing the E-value, Ann Intern Med
Wang, Hu, Hu, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, erratum in Lancet
Zhu, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit